A compound of the formula I: wherein: A is selected from the group consisting of: pyridyl, quinolinyl, cyclopentapyridinyl and tetrahydroquinolinyl, said pyridyl, quinolinyl, and cyclopentapyridinyl optionally substituted with 1 to 3 groups of R a W is cycylopropyl or -CH(CH 3)-CH 2 - R 4 is selected from the group consisting of: oxazolyl, oxadiazolyl, triazolyl, isoxazolone, pyrazolone, pyrazolopyridinyl, dioxaspirodecanyl, pyrazinyl, pyrrolyl, imidazopyridinyl, pyrimidinyl, indolyl, pyranone, pyranyl, pyridazinyl, furanone, isothiazolyl, dihydropyrazolone, phenyl, cyclohexanone, cyclohexyl, cyclohexenone, cyclopentenone cyclopentanone, cyclopentanyl, pyridinone C 2-6 alkenyl, said group through optionally substituted with 1 to 3 groups of R a', R a selected from the group consisting of: m C 1-4, haloalkyl, said alkyl optionally substituted with 1 to 3 groups of R b, halogen, OR, C 1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents selected from Rb, C 3-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents selected from Rb, -O(CH 2) n cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents selected from Rb, C 5-10 heterocyclyl, where the heterocyclyl is unsubstituted or substituted with one or more substituents selected from Rb, -(C=O) m -N 2, -CO 2 R, -CN, -O-, -O CH 2 OR, and S pR; R b is selected from the group consisting of: (CH 2)nOR, CF 3, CF 2 C 1-6 alkyl, cyano, N 2, halogen; R is selected from the group consisting of: hydrogen, C 1-6 alkyl, said alkyl optionally substituted with 1 to 3 groups of R b, and m C 1-4, haloalkyl, m is 0 or 1, n is 0, 1, 2, 3, or 4, p is 1 or 2, or a pharmaceutically acceptable salt thereof, with the proviso that when R 4 is pyridinone then A cannot be pyridyl; A is not methoxypyridyl when R 4 is imidazopyridine; when A is methoxypyridyl then R 4 is not methyltriazole and when A is methylpyridyl or methoxypyridyl and R 4 is a substituted cyclohexyl or cyclohexenol then the substituent can't only be a hydroxyl group. A is selected from the group consisting of: pyridyl, quinolinyl, cyclopentapyridinyl and tetrahydroquinolinyl, pyridyl, quinolinyl, cyclopentapyridinyl and tetrahydroquinolinyl, said pyridyl, quinolinyl, and cyclopentapyridinyl optionally substituted with 1 to 3 groups of R a W is cycylopropyl or -CH(CH 3)-CH 2 - R 4 is selected from the group consisting of: oxazolyl, oxadiazolyl, triazolyl, isoxazolone, pyrazolone, pyrazolopyridinyl, dioxaspirodecanyl, pyrazinyl, pyrrolyl, imidazopyridinyl, pyrimidinyl, indolyl, pyranone, pyranyl, pyridazinyl, furanone, isothiazolyl, dihydropyrazolone, phenyl, cyclohexanone, cyclohexyl, cyclohexenone, cyclopentenone cyclopentanone, cyclopentanyl, pyridinone C 2-6 alkenyl, oxazolyl, oxadiazolyl, triazolyl, isoxazolone, pyrazolone, pyrazolopyridinyl, dioxaspirodecanyl, pyrazinyl, pyrrolyl, imidazopyridinyl, pyrimidinyl, indolyl, pyranone, pyranyl, pyridazinyl, furanone, isothiazolyl, dihydropyrazolone, phenyl, cyclohexanone, cyclohexyl, cyclohexenone, cyclopentenone cyclopentanone, cyclopentanyl, pyridinone C 2-6 alkenyl, said group through optionally substituted with 1 to 3 groups of R a', R a selected from the group consisting of: m C 1-4, haloalkyl, said alkyl optionally substituted with 1 to 3 groups of R b, halogen, OR, C 1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents selected from Rb, C 3-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents selected from Rb, -O(CH 2) n cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents selected from Rb, C 5-10 heterocyclyl, where the heterocyclyl is unsubstituted or substituted with one or more substituents selected from Rb, -(C=O) m -N 2, -CO 2 R, -CN, -O-, -O CH 2 OR, and S pR; m C 1-4, haloalkyl, said alkyl optionally substituted with 1 to 3 groups of R b, halogen, OR, C 1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents selected from Rb, C 3-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents selected from Rb, -O(CH 2) n cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents selected from Rb, C 5-10 heterocyclyl, where the heterocyclyl is unsubstituted or substituted with one or more substituents selected from Rb, -(C=O) m -N 2, -CO 2 R, -CN, -O-, -O CH 2 OR, and S pR; R b is selected from the group consisting of: (CH 2)nOR, CF 3, CF 2 C 1-6 alkyl, cyano, N 2, halogen; (CH 2)nOR, CF 3, CF 2 C 1-6 alkyl, cyano, N 2, halogen; R is selected from the group consisting of: hydrogen, C 1-6 alkyl, said alkyl optionally substituted with 1 to 3 groups of R b, and m C 1-4, haloalkyl, hydrogen, C 1-6 alkyl, said alkyl optionally substituted with 1 to 3 groups of R b, and m C 1-4, haloalkyl, m is 0 or 1, n is 0, 1, 2, 3, or 4, p is 1 or 2, or a pharmaceutically acceptable salt thereof, with the proviso that when R 4 is pyridinone then A cannot be pyridyl; A is not methoxypyridyl when R 4 is imidazopyridine; when A is methoxypyridyl then R 4 is not methyltriazole and when A is methylpyridyl or methoxypyridyl and R 4 is a substituted cyclohexyl or cyclohexenol then the substituent can't only be a hydroxyl group.